Clinical Trial Update: A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy [Phase 2]

View source ↗

Summary

This is a phase 2 clinical trial update on pembrolizumab plus olaparib for metastatic pancreatic ductal adenocarcinoma with homologous recombination deficiency;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD) | Phase 2 | Status: ACTIVE_NOT_RECRUITING